CYP2C19 Linked to Plavix Response, Higher AE Risk, New Studies Show

Two new studies published in the New England Journal of Medicine found that patients with reduced-function alleles of CYP2C19 who had been treated with clopidogrel have a higher rate of major cardiovascular events than those without the alleles. One of the studies was funded by Eli Lilly and Daiichi Sankyo, companies that currently have a competing anti-platelet agent under review at the US Food and Drug Administration.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories